secwatch.observer — SEC 8-K summary
======================================

Issuer:     Context Therapeutics Inc. (CNTX)
CIK:        0001842952
Form:       8-K
Filed at:   2023-10-31T23:59:59+00:00
Accession:  0001842952-23-000082
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Context Therapeutics reports preclinical CTIM-76 data showing tumor regressions; IND on track for Q1 2024
--------------------------------------------------------------------------------

- CTIM-76 induced dose-proportional tumor regressions and was well tolerated in xenograft models.
- CTIM-76 showed ten-fold higher potency than AMG-794 in in vitro cytotoxicity and cytokine activation assays.
- CTIM-76 retained activity across low to high CLDN6 expression, unlike TORL-1-23 which depended on high expression.
- IND filing for CTIM-76 planned for late Q1 2024.
- Approximately 70,000 US patients with CLDN6-positive metastatic solid tumors have no approved targeted treatment.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1842952/000184295223000082/0001842952-23-000082-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1842952/000184295223000082/cntx-20231031.htm
  HTML page:      https://secwatch.observer/filing/0001842952-23-000082

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer